Finance

Beta
Lists
002720:KRX
Kukje Pharma Co Ltd
₩3,520.00
+1.88%
(+65.00) 1D
Jun 12, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 002720...
Open
₩3,550
High
₩3,580
Low
₩3,455
Mkt. cap
74.48B
Avg. vol.
125.61K
Volume
0.00
Dividend
0.85%
Quarterly dividend
₩8
Ex-dividend date
Mar 12, 2026
P/E ratio
12.12
52-wk high
₩5,470
52-wk low
₩3,155
EPS
₩290
Shares outstanding
21.16M
No. of employees
244
Open
₩3,550
High
₩3,580
Low
₩3,455
Mkt. cap
74.48B
Avg. vol.
125.61K
Volume
0.00
Dividend
0.85%
Quarterly dividend
₩8
Ex-dividend date
Mar 12, 2026
P/E ratio
12.12
52-wk high
₩5,470
52-wk low
₩3,155
EPS
₩290
Shares outstanding
21.16M
No. of employees
244
News stories
From sources across the web
About Kukje Pharma Co Ltd
CEO-
Employees244
Founded1959
Headquarters-
SectorPharmaceutical industry
Websitekukjepharm.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
45.02B
45.63B
43.34B
43.98B
Cost of goods sold
20.29B
20.70B
21.74B
20.17B
Cost of revenue
20.29B
20.70B
21.74B
20.17B
Research and development expenses
551.50M
658.59M
1.79B
931.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.86B
22.13B
21.36B
20.66B
Operating expense
21.22B
23.02B
23.14B
21.85B
Total operating expenses
41.51B
43.72B
44.88B
42.01B
Operating income
3.51B
1.92B
-1.54B
1.97B
Other non operating income
238.76M
392.85M
195.68M
199.95M
EBT including unusual items
3.33B
2.42B
-1.54B
2.62B
EBT excluding unusual items
3.33B
2.41B
-1.34B
2.60B
Income tax expense
665.53M
505.72M
-808.40M
477.03M
Effective tax rate
19.98%
20.87%
52.36%
18.20%
Other operating expenses
-
-
-
-
Net income
2.66B
1.91B
-731.53M
2.15B
Net profit margin
5.91%
4.19%
-1.69%
4.88%
Earnings per share
-
-
-
-
Interest and investment income
107.00M
139.49M
130.84M
77.28M
Interest expense
-245.06M
-218.61M
-198.95M
-188.96M
Net interest expenses
-138.06M
-79.12M
-68.10M
-111.69M
Depreciation and amortization charges
168.38M
167.22M
161.54M
168.12M
EBITDA
4.31B
2.73B
-723.71M
2.81B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer